Clinical trials: in Zimbabwe
HIV-1 Infection
Early ART to Limit Infection and Establishment of Reservoir
The study was done to: Start antiretroviral therapy (ART) early in those recently or acutely infected with HIV-1 See how starting ART as soon as the infection is found affects the amount of HIV-1 in blood and how well the body…
- Trial name
- EARLIER (NCT02859558)
- Testing
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Where
- 30 sites in United States, Brazil and 4 more
- Volunteers
- 195 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy
The purpose of this study is to evaluate the maternal and infant safety of the dapivirine (DPV) vaginal ring (VR) and daily oral Truvada in HIV-uninfected pregnant women and their infants.
- Trial name
- NCT03965923
- Testing
- Dapivirine (DPV) Vaginal Ring (VR), Truvada Tablet
- Where
- 4 sites in Malawi, South Africa and 2 more
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Tuberculosis
Choice Architecture Based TB Preventive Therapy Prescribing
Background: Clinical guidelines and policies often fail to achieve high levels of delivery of intended clinical interventions. The difference in what investigators know works and what is actually delivered at the clinic-level to…
- Trial name
- CAT (NCT04466293)
- Testing
- Choice Architecture
- Where
- 3 sites in Malawi, Mozambique and 1 more
- Volunteers
- 57 people
- Sponsor
- Johns Hopkins University
STI
Comparing a Novel Point-of-care Cytokine Biomarker Lateral Flow Test With Nucleic Acid Amplification Tests for Detection of Sexually Transmitted Infections and Bacterial Vaginosis
1. To evaluate the performance of a lateral flow POC test, namely the Genital InFlammation Test (GIFT), for identifying women with inflammatory STIs and BV, who are at higher risk of HIV infection and reproductive complications…
- Trial name
- GIFT (NCT05723484)
- Testing
- GIFT Device
- Where
- 3 sites in Madagascar, South Africa and 1 more
- Volunteers
- 675 people
- Sponsor
- University of Cape Town
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
Tuberculosis, MDR
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among…
- Trial name
- PHOENIx MDR-TB (NCT03568383)
- Testing
- Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
- Where
- 31 sites in Botswana, Brazil and 11 more
- Volunteers
- 5,832 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
To assess the acceptance rate, adherence, acceptability, and continuation of oral pre-exposure prophylaxis (PrEP) among young southern African women.
- Trial name
- NCT02732730
- Testing
- Truvada, Drug level counseling at Weeks 8 and 13
- Where
- 3 sites in South Africa, Zimbabwe
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV Infections
Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention
Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination.
- Trial name
- IMPERATIVE (NCT06370923)
- Testing
- Peer Distribution, Community Health Worker Distribution
- Where
- Zimbabwe
- Volunteers
- 3,591 people, healthy volunteers welcome
- Sponsor
- University of Stellenbosch
HIV Prevention
The CATALYST Study
The CATALYST study is an implementation study that will characterize and assess the implementation of an enhanced service delivery package providing informed choice of pre-exposure prophylaxis (PrEP) products among women at…
- Trial name
- NCT05937698
- Where
- 28 sites in Kenya, Lesotho and 3 more
- Volunteers
- 6,069 people, healthy volunteers welcome
- Sponsor
- FHI 360
Safety, Acceptability
Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings
This research study is being conducted to find out how easy, comfortable, and safe intravaginal rings are for women to use. The two rings used in this study do not dispense any medications, are the same size, but differ in their…
- Trial name
- MATRIX-003 (NCT06163274)
- Where
- 5 sites in United States, South Africa and 1 more
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
HIV Infections
Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum
The purpose of this study was to evaluate the pharmacokinetics, feasibility, acceptability, and safety of a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as oral daily pre-exposure…
- Trial name
- NCT03386578
- Testing
- Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Behavioral HIV risk reduction package, Enhanced adherence support
- Where
- 7 sites in Malawi, South Africa and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Men
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
The long term objective is to develop a gel to be used as a male contraceptive.
- Conditions
- Healthy, Men, Male Contraception
- Trial name
- NCT03452111
- Testing
- Nestorone + Testosterone Combination Gel
- Where
- 17 sites in United States, Chile and 5 more
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Premier Research
HIV Infections
A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants
Part A: The purpose of this part of the study is to understand how the body's immune system responds to a new lab-made antibody against HIV.
- Trial name
- NCT05184452
- Testing
- PGDM1400LS (5mg/kg, IV), PGDM1400LS (20mg/kg, IV), PGDM1400LS (20mg/kg, SC)
- Where
- 13 sites in United States, Kenya and 2 more
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Body Composition Sub-study of the D2EFT Trial
This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle…
- Trial name
- NCT03675815
- Testing
- Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs
- Where
- 7 sites in India, Malaysia and 3 more
- Volunteers
- 155 people
- Sponsor
- Kirby Institute
Safety, Acceptability
MATRIX-002: Trial to Assess Acceptability and Safety of Two Placebo Vaginal Films
This study will enroll approximately 100 HIV-negative persons, aged18-45 years, and assigned female sex at birth from sites in the United States, Kenya, South Africa, and Zimbabwe.
- Conditions
- Safety, Acceptability, Usability
- Trial name
- NCT06046053
- Where
- 5 sites in United States, Kenya and 2 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rohan, Lisa, PhD
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB).
- Trial name
- S31/A5349 (NCT02410772)
- Testing
- rifapentine, rifapentine and moxifloxacin, control
- Where
- 33 sites in United States, Brazil and 11 more
- Volunteers
- 2,516 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV…
- Trial name
- NCT04824131
- Testing
- Oral cabotegravir (CAB), CAB LA, Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Where
- 3 sites in South Africa, Uganda and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe
The purpose of this study is to determine whether community-based peer education and condom distribution combined with improved treatment of sexually transmitted infections are effective in reducing the spread of HIV infection in…
- Trial name
- NCT00390949
- Testing
- Peer education among commercial sex workers and clients, Condom distribution and promotion, Syndromic treatment of sexually transmitted infections
- Where
- Zimbabwe
- Volunteers
- 9,454 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV Infection
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
People with HIV have a high chance of becoming infected with TB, especially when they live in areas where TB infection is common. It can be difficult to diagnose TB in people who need to start HIV treatment right away.
- Trial name
- REMEMBER (NCT01380080)
- Testing
- Atripla (r), Efavirenz, Truvada
- Where
- 18 sites in Brazil, Haiti and 8 more
- Volunteers
- 851 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections